Academic Journal
Q1Journal of Hematology and Oncology
About Journal of Hematology and Oncology
Journal of Hematology and Oncology is a scholarly journal published by BioMed Central Ltd. SCImago 2025 places it in Q1 with an SJR of 11.824 and an H-index of 194.
Its listed coverage is 2008-2026 and its research categories include Cancer Research (Q1); Hematology (Q1); Molecular Biology (Q1); Oncology (Q1). The 2025 dataset reports 110 documents and 12988 citations across the latest three-year reporting window.
The Journal of Hematology and Oncology is a peer-reviewed scientific journal dedicated to publishing high-quality research in the fields of hematology and oncology. With its comprehensive focus on blood disorders and cancer, the journal serves as a valuable resource for clinicians, researchers, and healthcare professionals who aim to stay updated on the latest advancements in these critical medical areas.
A Broad Scope of Research
The journal’s content spans a wide array of topics in both hematology and oncology. It covers basic science, clinical studies, molecular biology, immunotherapy, and innovative treatments for a range of blood disorders such as leukemia, lymphoma, anemia, hemophilia, and more. Additionally, it delves deep into various cancers, including but not limited to breast, lung, prostate, and colorectal cancer. Researchers and practitioners use the journal to gain insights into novel diagnostic techniques, emerging therapies, and potential biomarkers that could revolutionize the treatment of these conditions.
Impactful Research and Publications
The Journal of Hematology and Oncology aims to foster progress in understanding the mechanisms of hematologic and oncologic diseases. The research published in this journal often focuses on translational and clinical studies that aim to bridge the gap between laboratory discoveries and real-world applications in patient care. The publication of groundbreaking research can drive new therapeutic strategies, improve patient outcomes, and offer new hope for individuals affected by these life-threatening conditions.
As a leading journal in the field, it provides a platform for researchers worldwide to publish their findings and collaborate with experts in hematology and oncology. It regularly features articles on drug development, cancer genomics, personalized medicine, immunotherapy, and advances in stem cell therapies. These areas are vital as they not only provide new treatments but also offer insights into preventative measures, which are crucial for improving patient survival rates and quality of life.
Research Methodologies and Innovations
One of the journal’s main objectives is to highlight innovative research methodologies that enhance the understanding of hematological and oncological diseases. For instance, cutting-edge technologies like CRISPR gene editing, next-generation sequencing, and artificial intelligence are increasingly being applied in research studies, which opens up new possibilities in disease treatment and management.
The journal also focuses on clinical trial results and their implications on everyday patient care. By publishing findings from large-scale trials, the journal informs clinicians about the most effective and up-to-date treatment regimens, making it easier for them to incorporate the latest breakthroughs into their practice.
A Resource for Healthcare Professionals
Beyond academic circles, the Journal of Hematology and Oncology is an essential resource for healthcare providers involved in treating patients with blood disorders and cancer. It allows professionals to keep abreast of the latest clinical guidelines, diagnostic procedures, and patient management strategies, ensuring that care provided is based on the most current evidence.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Journal of Hematology and Oncology is a distinguished, peer-reviewed publication that provides cutting-edge research, clinical studies, and advancements in the fields of hematology and oncology. Serving as an essential resource for healthcare professionals, researchers, and students, this journal aims to contribute to the ongoing global fight against blood disorders and cancer by delivering high-quality, evidence-based insights. The scope of the journal is broad, covering a wide range of topics related to hematology and oncology, focusing on the latest developments in both scientific research and clinical practice.
Key Areas of Focus
-
Hematology Research
The journal highlights significant developments in the study of blood disorders, including but not limited to anemia, leukemia, lymphoma, hemophilia, sickle cell disease, and thrombosis. Articles often focus on novel diagnostic methods, therapeutic advancements, and understanding the molecular biology behind these conditions. It also addresses the latest trends in bone marrow transplantation, stem cell therapies, and the exploration of innovative treatments aimed at improving patient outcomes in hematologic diseases. -
Oncology Studies
Cancer research takes center stage in the Journal of Hematology and Oncology, where both solid tumors and hematologic malignancies are covered extensively. This includes comprehensive studies on breast cancer, lung cancer, prostate cancer, gastrointestinal cancers, as well as hematologic cancers like leukemia, lymphoma, and multiple myeloma. The journal presents groundbreaking research on chemotherapy, immunotherapy, radiotherapy, targeted therapy, and personalized medicine that aim to improve survival rates and quality of life for cancer patients. -
Clinical Trials and Case Reports
The journal frequently publishes results from clinical trials, offering valuable insights into the efficacy and safety of various treatment modalities. Case reports documenting unique, complex, or rare hematologic and oncological cases are also featured, allowing for the exchange of real-world experiences among medical professionals. These case reports help in improving clinical decision-making and providing practical learning for clinicians. -
Molecular and Translational Oncology
The integration of molecular biology with clinical oncology is a vital aspect of modern cancer treatment. The Journal of Hematology and Oncology covers research into genetic mutations, molecular markers, and biomarkers that facilitate early cancer detection, prognosis, and the development of precision therapies. Articles often focus on the translation of laboratory findings into clinical applications, which is essential for personalized treatment plans. -
Immuno-Oncology
Immunotherapy is one of the most rapidly advancing areas in oncology, and the journal explores the use of immune checkpoint inhibitors, CAR T-cell therapy, and vaccines for cancer treatment. Research on how to harness the body’s immune system to target cancer cells continues to be a critical area of focus, and the journal provides a platform for disseminating the latest breakthroughs in immuno-oncology. -
Pediatric Hematology and Oncology
A significant portion of the journal’s scope is dedicated to pediatric hematology and oncology, covering rare blood disorders and cancers affecting children and adolescents. Research in this area often addresses the challenges of diagnosing and treating pediatric cancers, exploring novel therapies, and enhancing survivorship care for young patients. -
Multidisciplinary Approaches
The Journal of Hematology and Oncology encourages multidisciplinary research, recognizing that collaboration between hematologists, oncologists, radiologists, pathologists, pharmacologists, and nurses is essential for providing comprehensive care to patients. The journal fosters the exchange of ideas and methods from different medical disciplines to enhance treatment efficacy and patient care.
Recent Research Articles
Latest publications matched automatically by ISSN.
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
Jiacheng Lou, Yizhu Lyu
2026-09-09 · DOI: 10.1186/s13045-026-01843-1Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances
Yufang Wang, Jing Zheng, Zhen Li, Jingjing Qu et al.
2026-09-05 · DOI: 10.1186/s13045-026-01842-2High-definition spatial transcriptomics visualizes the cellular and molecular architecture underlying perineural invasion in localized prostate cancer
Paul Vinu Salachan, Line Raaby, Jacob Fredsøe, Benedicte Ulhøi et al.
2026-09-01 · DOI: 10.1186/s13045-026-01841-3Mucosal immunity: mechanism and application in cancer immunotherapy
Maosen Xu, Ruolan Xia, Yuquan Wei, Xingchen Peng et al.
2026-09-01 · DOI: 10.1186/s13045-026-01829-zGlutathione reductase deficiency potentiates the immunogenicity of ferroptosis and cuproptosis via amplified reactive oxygen species accumulation and cGAS-STING pathway activation
Xiaoyi Deng, Zaidong Deng, Bin Zhu, Ruiqi Hu et al.
2026-09-01 · DOI: 10.1186/s13045-026-01840-4Current and future therapies for triple-negative breast cancer
Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu, Yu-Ling Xiao et al.
2026-08-26 · DOI: 10.1186/s13045-026-01839-xPlasma biomarkers predicting development of lung cancer 5 years before diagnosis
Kostas A. Papavassiliou, Athanasios G. Papavassiliou
2026-08-14 · DOI: 10.1186/s13045-026-01838-yCorrection: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies
Daruka Mahadevan, Minal Barve, Devalingam Mahalingam, Jay Parekh et al.
2026-08-10 · DOI: 10.1186/s13045-026-01837-zThe KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026
Serena Pillozzi, Elisa Giommoni, Giulia Petroni, Daniele Rossini et al.
2026-08-08 · DOI: 10.1186/s13045-026-01834-2A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm
Lihua E. Budde, Marissa M. Del Real, Joo Song, Tracey Stiller et al.
2026-08-07 · DOI: 10.1186/s13045-026-01833-3A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection
Ángel Ramírez-Fernández, Adham S. Bear, Elahe Kamali, Robert Bartoszek et al.
2026-07-30 · DOI: 10.1186/s13045-026-01836-0CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment
Monika Szczepanowski, Johanna Richter, Sonja Bendig, Lorenz Bastian et al.
2026-07-20 · DOI: 10.1186/s13045-026-01832-4Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data
Ming-Yu Lai, Hao-Xiang Wu, Ming-Ming He, Wen-Long Guan et al.
2026-07-20 · DOI: 10.1186/s13045-026-01830-6Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities
Guoqing Li, Wenlong Wang
2026-07-18 · DOI: 10.1186/s13045-026-01831-5Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications
Jingyu Tan, Tao Wen, Jian Liu, Xiaoli Ru et al.
2026-07-10 · DOI: 10.1186/s13045-026-01828-0Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors
Ignacio Melero, María de Miguel, Elena Garralda Cabanas, Guillermo de Velasco et al.
2026-07-09 · DOI: 10.1186/s13045-026-01818-2From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine
Liyuan Qiao, Leyang Wu, Yihan Xiao, Jiahui Qiu et al.
2026-07-07 · DOI: 10.1186/s13045-026-01827-1Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities
Yuqian Li, Xinlin Liu, Fuyuan Zhang, Rong Fu et al.
2026-07-06 · DOI: 10.1186/s13045-026-01824-4Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting
Yan-Ruide Li, Zhengyao Shao, Haochen Nan
2026-07-03 · DOI: 10.1186/s13045-026-01823-5KRAS inhibition is an effective therapy for appendiceal adenocarcinoma
Saikat Chowdhury, Ichiaki Ito, Vinay K. Pattalachinti, Abdelrahman M. G. Yousef et al.
2026-07-02 · DOI: 10.1186/s13045-026-01817-3Reviews
Community Reviews
Version History
April 18, 2025 at 10:13 am
April 18, 2025